文献速递类风湿关节炎

早期类风湿关节炎达标治疗策略的十年结局

Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2026-09-22

ARCTIC 试验纳入 230 例早期类风湿关节炎患者,实施严格达标治疗 2 年,10 年随访时 82% 患者处于 DAS 缓解,影像学进展有限,躯体功能与健康相关生活质量接近人群常模,早期持续缓解与更优长期结局相关。

要点

  • 早期达标治疗 10 年后 82% 患者处于 DAS 缓解,影像学进展有限。
  • 10 年时躯体功能与健康相关生活质量接近一般人群水平。
  • 2 年内达到持续 DAS 缓解者 10 年疾病活动度更低、躯体功能更好。

核心结论

  • 早期达标治疗策略下,10 年临床、结构和功能结局保持良好。
  • 早期持续缓解与 10 年更高缓解率和更好躯体功能相关。

研究设计与样本

  • ARCTIC 随机试验纳入 230 例早期类风湿关节炎患者,实施严格达标治疗 2 年。
  • 邀请参与者进行 10 年随访,评估疾病活动度、影像学损伤、躯体功能和生存。
  • 按 ARCTIC 期间是否达到持续缓解分层比较结局。

主要发现

  • 230 例中 218 例(95%)10 年时存活,179 例(82%)参与随访研究。
  • 82% 患者在诊断后 10 年处于 DAS 缓解。
  • 总 van der Heijde 改良 Sharp 评分从基线至 10 年中位变化 2.0(IQR 0.5, 4.5)。
  • 躯体功能和健康相关生活质量显著改善,接近人群常模。
  • 生存与一般人群相当;2 年时持续 DAS 缓解者 10 年疾病活动度更低、躯体功能更高。

关键数值与推荐

  • 10 年时 82% 患者处于 DAS 缓解。
  • 总 van der Heijde 改良 Sharp 评分中位变化 2.0(IQR 0.5, 4.5)。
  • 230 例中 218 例(95%)10 年存活,179 例(82%)参与随访。

临床怎么用

  • 早期类风湿关节炎应尽早实施严格达标治疗以争取持续缓解。
  • 早期持续缓解可作为预测长期良好结局的重要指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study is to examine 10-year clinical, structural and functional outcomes in patients with rheumatoid arthritis (RA) treated with an early treat-to-target strategy, and to examine whether achievement of sustained remission in early disease is associated with favourable long-term outcomes. METHODS: The ARCTIC (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen) trial enrolled 230 patients with early RA and applied a strict treat-to-target strategy for 2 years. Participants were invited to a 10-year follow-up, and disease activity, radiographic damage, physical function, and survival were assessed. Patients were stratified according to achievement of sustained remission in ARCTIC and outcomes were compared between groups. RESULTS: Of the 230 patients with ARCTIC, 218 (95%) were alive at 10 years and 179 (82%) participated in the follow-up study. Eighty-two per cent of patients were in Disease Activity Score (DAS) remission 10 years after diagnosis. Radiographic progression was limited, with a median (IQR) change in total van der Heijde modified Sharp score of 2.0 (0.5, 4.5) from baseline to 10 years. Physical function and health-related quality of life improved substantially, approaching population norms. Survival was comparable to that of the general population. Patients who achieved sustained DAS remission at 2 years had lower disease activity and higher physical function at the 10-year follow-up than those who did not. CONCLUSIONS: In this cohort of patients treated according to an early treat-to-target strategy, clinical, structural, and functional outcomes remained favourable at 10 years. Achievement of sustained remission in early disease was associated with higher remission rates and better physical function at 10 years. These findings support current treatment recommendations.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nordberg LB, Sundlisæter NP, Brinkmann GH, et al. Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis. Ann Rheum Dis. 2026. PMID: 42881069. doi:10.1016/j.ard.2026.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。